The quality on the proof is good, from research at minimal hazard of bias, of long duration, with clinically helpful outcomes, and with massive quantities of individuals. A very important locating is that some patients is not going to have a valuable gain with pregabalin, and for all those individuals another therapeutic intervention must be tried.